Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Dose-Lowering in Contrast-Enhanced MRI of the Central Nervous System: A Retrospective, Parallel-Group Comparison Using Gadobenate Dimeglumine

MC. DeLano, MV. Spampinato, EY. Chang, RG. Barr, RJ. Lichtenstein, C. Colosimo, J. Vymazal, Z. Wen, DDM. Lin, MA. Kirchin, G. Pirovano

. 2021 ; 54 (5) : 1660-1675. [pub] 20210520

Language English Country United States

Document type Journal Article, Multicenter Study, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc22003323

BACKGROUND: Concerns over gadolinium (Gd) retention encourage the use of lower Gd doses. However, lower Gd doses may compromise imaging performance. Higher relaxivity gadobenate may be suited to reduced dose protocols. PURPOSE: To compare 0.05 mmol/kg and 0.1 mmol/kg gadobenate in patients undergoing enhanced MRI of the central nervous system (CNS). STUDY TYPE: Retrospective, multicenter. POPULATION: Three hundred and fifty-two patients receiving 0.05 (n = 181) or 0.1 (n = 171) mmol/kg gadobenate. FIELD STRENGTH/SEQUENCES: 1.5 T and 3.0 T/precontrast and postcontrast T1-weighted spin echo/fast spin echo (SE/FSE) and/or gradient echo/fast field echo (GRE/FFE); precontrast T2-weighted FSE and T2-FLAIR. ASSESSMENT: Images of patients with extra-axial lesions at 1.5 T or any CNS lesion at 3.0 T were reviewed by three blinded, independent neuroradiologists for qualitative (lesion border delineation, internal morphology visualization, contrast enhancement; scores from 1 = poor to 4 = excellent) and quantitative (lesion-to-brain ratio [LBR], contrast-to-noise ratio [CNR]; SI measurements at regions-of-interest on lesion and normal parenchyma) enhancement measures. Noninferiority of 0.05 mmol/kg gadobenate was determined for each qualitative endpoint if the lower limit of the 95% confidence interval (CI) for the difference in precontrast + postcontrast means was above a noninferiority margin of -0.4. STATISTICAL TESTS: Student's t-test for comparison of mean qualitative endpoint scores, Wilcoxon signed rank test for comparison of LBR and CNR values; Wilcoxon rank sum test for comparison of SI changes. Tests were significant for P < 0.05. RESULTS: The mean change from precontrast to precontrast + postcontrast was significant for all endpoints. Readers 1, 2, and 3 evaluated 304, 225, and 249 lesions for 0.05 mmol/kg gadobenate, and 382, 309, and 298 lesions for 0.1 mmol/kg gadobenate. The lower limit of the 95% CI was above -0.4 for all comparisons. Significantly, higher LBR and CNR was observed with the higher dose. DATA CONCLUSION: 0.05 mmol/kg gadobenate was noninferior to 0.1 mmol/kg gadobenate for lesion visualization. EVIDENCE LEVEL: 2 TECHNICAL EFFICACY: Stage 3.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003323
003      
CZ-PrNML
005      
20220127150336.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jmri.27731 $2 doi
035    __
$a (PubMed)34018290
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a DeLano, Mark C $u Spectrum Health System, Advanced Radiology Services PC, Division of Radiology and Biomedical Imaging, College of Human Medicine, Michigan State University, Michigan, USA
245    10
$a Dose-Lowering in Contrast-Enhanced MRI of the Central Nervous System: A Retrospective, Parallel-Group Comparison Using Gadobenate Dimeglumine / $c MC. DeLano, MV. Spampinato, EY. Chang, RG. Barr, RJ. Lichtenstein, C. Colosimo, J. Vymazal, Z. Wen, DDM. Lin, MA. Kirchin, G. Pirovano
520    9_
$a BACKGROUND: Concerns over gadolinium (Gd) retention encourage the use of lower Gd doses. However, lower Gd doses may compromise imaging performance. Higher relaxivity gadobenate may be suited to reduced dose protocols. PURPOSE: To compare 0.05 mmol/kg and 0.1 mmol/kg gadobenate in patients undergoing enhanced MRI of the central nervous system (CNS). STUDY TYPE: Retrospective, multicenter. POPULATION: Three hundred and fifty-two patients receiving 0.05 (n = 181) or 0.1 (n = 171) mmol/kg gadobenate. FIELD STRENGTH/SEQUENCES: 1.5 T and 3.0 T/precontrast and postcontrast T1-weighted spin echo/fast spin echo (SE/FSE) and/or gradient echo/fast field echo (GRE/FFE); precontrast T2-weighted FSE and T2-FLAIR. ASSESSMENT: Images of patients with extra-axial lesions at 1.5 T or any CNS lesion at 3.0 T were reviewed by three blinded, independent neuroradiologists for qualitative (lesion border delineation, internal morphology visualization, contrast enhancement; scores from 1 = poor to 4 = excellent) and quantitative (lesion-to-brain ratio [LBR], contrast-to-noise ratio [CNR]; SI measurements at regions-of-interest on lesion and normal parenchyma) enhancement measures. Noninferiority of 0.05 mmol/kg gadobenate was determined for each qualitative endpoint if the lower limit of the 95% confidence interval (CI) for the difference in precontrast + postcontrast means was above a noninferiority margin of -0.4. STATISTICAL TESTS: Student's t-test for comparison of mean qualitative endpoint scores, Wilcoxon signed rank test for comparison of LBR and CNR values; Wilcoxon rank sum test for comparison of SI changes. Tests were significant for P < 0.05. RESULTS: The mean change from precontrast to precontrast + postcontrast was significant for all endpoints. Readers 1, 2, and 3 evaluated 304, 225, and 249 lesions for 0.05 mmol/kg gadobenate, and 382, 309, and 298 lesions for 0.1 mmol/kg gadobenate. The lower limit of the 95% CI was above -0.4 for all comparisons. Significantly, higher LBR and CNR was observed with the higher dose. DATA CONCLUSION: 0.05 mmol/kg gadobenate was noninferior to 0.1 mmol/kg gadobenate for lesion visualization. EVIDENCE LEVEL: 2 TECHNICAL EFFICACY: Stage 3.
650    _2
$a mozek $x diagnostické zobrazování $7 D001921
650    12
$a nádory mozku $7 D001932
650    _2
$a kontrastní látky $7 D003287
650    _2
$a diethylentriaminpentaacetát gadolinia $7 D019786
650    _2
$a lidé $7 D006801
650    _2
$a magnetická rezonanční tomografie $7 D008279
650    _2
$a meglumin $x analogy a deriváty $7 D008536
650    12
$a organokovové sloučeniny $7 D009942
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Spampinato, Maria Vittoria $u Department of Radiology and Radiological Science, Medical University of South Carolina, Charleston, South Carolina, USA
700    1_
$a Chang, Eric Y $u Radiology Service, VA San Diego Healthcare System, San Diego, California, USA
700    1_
$a Barr, Richard G $u Department of Radiology, Rootstown, Northeastern Ohio Medical University, Rootstown, Ohio, USA
700    1_
$a Lichtenstein, Richard J $u Department of Radiology, Sarasota Memorial Hospital, Sarasota, Florida, USA
700    1_
$a Colosimo, Cesare $u Institute of Radiology, Radiodiagnostica e Neuroradiologia, Fondazione Policlinico Universitario "A. Gemelli", Università Cattolica del Sacro Cuore, Rome, Italy
700    1_
$a Vymazal, Josef $u Department of Radiology, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Wen, Zhibo $u Department of Radiology, Zhujiang Hospital, Southern Medical University, Guangzhou, China
700    1_
$a Lin, Doris D M $u Division of Neuroradiology, Russell H. Morgan Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
700    1_
$a Kirchin, Miles A $u Global Medical & Regulatory Affairs, Bracco Imaging SpA, Milan, Italy
700    1_
$a Pirovano, Gianpaolo $u Global Medical & Regulatory Affairs, Bracco Diagnostics Inc., Monroe, New Jersey, USA
773    0_
$w MED00004911 $t Journal of magnetic resonance imaging : JMRI $x 1522-2586 $g Roč. 54, č. 5 (2021), s. 1660-1675
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34018290 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150332 $b ABA008
999    __
$a ok $b bmc $g 1750939 $s 1154472
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 54 $c 5 $d 1660-1675 $e 20210520 $i 1522-2586 $m Journal of magnetic resonance imaging $n J Magn Reson Imaging $x MED00004911
LZP    __
$a Pubmed-20220113
Back

Find record

Citation metrics

Archiving options